Welcome to our dedicated page for Mei Pharma SEC filings (Ticker: MEIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to gauge MEI Pharma’s cash runway or the impact of a phase 2 read-out means wading through dense biotech jargon and hundreds of pages of disclosures. From intricate R&D footnotes to sudden 8-K trial updates, MEI Pharma SEC filings can feel impenetrable—yet every detail matters when a single data point can move the share price.
Stock Titan delivers MEI Pharma SEC filings explained simply. Our AI-powered summaries break down each MEI Pharma quarterly earnings report 10-Q filing, highlight material events from MEI Pharma 8-K material events explained, and surface MEI Pharma insider trading Form 4 transactions in real time. Want dilution insight? The annual MEI Pharma annual report 10-K simplified pinpoints cash burn and shelf registrations. Curious about leadership moves? Get MEI Pharma executive stock transactions Form 4 with instant alerts. Each document is linked directly to EDGAR while our platform tags clinical milestones, partnership terms, and R&D spend so you can focus on decisions, not page counts.
Whether you are monitoring FDA timelines, benchmarking R&D expense trends, or checking the MEI Pharma proxy statement executive compensation, Stock Titan keeps you ahead. Use our AI to compare quarter-over-quarter trial costs, track MEI Pharma Form 4 insider transactions real-time, and receive concise MEI Pharma earnings report filing analysis the moment documents hit EDGAR. Understanding MEI Pharma SEC documents with AI means faster insights into pipeline progress, financing strategy, and management confidence—so you never miss a catalyst.
Amendment No. 9 to Schedule 13D – MEIP (filed 24-Jul-25)
The Cable Car/Anson activist coalition discloses that MEI Pharma’s 17-Jul-25 private placement diluted its combined stake below the 5 % reporting threshold. The group now owns 1,093,188 shares, or 3.7 % of the 29,879,755 shares outstanding, and therefore ceases to act as a Section 13(d) group. Individual holdings: Funicular Funds/Cable Car/J. Ma-Weaver 35,300 sh (0.1 %); Anson Investments Master 841,674 sh (2.8 %); Anson East Master 214,304 sh (0.7 %); Anson Opportunities Master 37,210 sh (0.1 %).
Because the “Minimum Ownership Amount” in the 2023 Cooperation Agreement was no longer satisfied, Anson-appointed director Taheer Datoo resigned effective 22-Jul-25. On the same date all parties executed mutual terminations of both the Cooperation Agreement and the Group Agreement. Each fund acquired its position for cash (≈ US $12.9 m aggregate) without margin financing and now disclaims beneficial ownership of shares it does not directly hold.
Implication: activist governance pressure and mandatory 13D amendments end, reducing the likelihood of further board or strategic agitation from these investors.
FAQ
What is the current stock price of Mei Pharma (MEIP)?
What is the market cap of Mei Pharma (MEIP)?
